Plain-English translation of NCT07344948 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new medication called that is being developed to treat schizophrenia. The study will evaluate whether the medication is safe and well-tolerated, and how your body absorbs and processes it. Researchers will start with very small doses and gradually increase them to find the safest, most effective dose.
Current schizophrenia treatments don't work well for everyone, and some people experience significant side effects. This trial is exploring whether this medication could become a new treatment option for people living with schizophrenia.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will either receive the new medication or a placebo (a pill with no active medicine). The study has two main phases: in the first phase, you will take a single dose and be monitored for safety; in the second phase, you will take daily doses for 10 consecutive days. Throughout the trial, you will have regular visits for blood tests, heart monitoring, and check-ins with the research team to ensure your safety.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Neurosterix
Enrollment target
~73 participants
Started
October 2025
Primary completion
May 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 55 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Doug Feltner, Chief Medical Officer, MD
Neurosterix
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.